Last reviewed · How we verify
NCT07244744
Tilrdakizumab Almirall
trial testing Tildrakizumab in Psoriasis in 3 participants. Participants enrolled and being followed up; not accepting new ones.
31 December 2024
Quick facts
| Lead sponsor | University Hospital Schleswig-Holstein |
|---|---|
| Status | Active, enrolled |
| Study type | OBSERVATIONAL |
| Enrollment | 3 |
| Start date | 27 June 2023 |
| Primary completion | 31 December 2024 |
| Estimated completion | 30 April 2026 |
| Sites | 1 location across Germany |
Drugs / interventions tested
- Tildrakizumab (TILDRAKIZUMAB) — full drug profile →
Conditions studied
- Psoriasis — all drugs for Psoriasis →
Sponsor
University Hospital Schleswig-Holstein
Who can join
18 and older, any sex, with Psoriasis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Define the mechanisms underlying the short- and the long-lasting effects of IL-23 targeting in plaque PsO, by characterizing the longitudinal effects of IL-23 inhibition on the ratio of Trm/Treg cells in the skin of moderate to severe plaque PsO patients. HDST (Visium HD) and HDSP (MICS) are used to characterize the early (2 weeks) and late (16 weeks) molecular effects of treatment with tildrakizumab on the skin of three patients with moderate to severe plaque psoriasis. Non-lesional and lesional skin samples taken at the start of treatment with tildrakizumab will be used, as well as healed skin adjacent to the original sampling sites at week 2 and week 16 after the start of treatment with tildrakizumab. The same samples will be examined using Visium HD and the MACSima imaging system.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07244744
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Tildrakizumab
Trials testing the same drug.
- NCT07352566 — Utilization of a Microdevice for Psoriasis and Atopic Dermatitis · Phase 4 · not yet recruiting
- NCT04823247 — Observational Real-world Evidence (RWE) Study to Assess Patient-reported Wellbeing Using Tildrakizumab in Live Setting - · completed
- NCT04971200 — Pilot Study Assessing the Effect of Tildrakizumab in Vitiligo · EARLY_PHASE1 · completed
- NCT03897075 — Efficacy and Safety Study of Tildrakizumab in the Treatment of Nail Psoriasis · Phase 3 · completed
- NCT04458311 — Abiraterone Acetate in Combination With Tildrakizumab · Phase 1, PHASE2 · terminated
Other recruiting trials for Psoriasis
Currently open trials in the same condition.
- NCT07471048 — A Study to Evaluate the Impact of a Magnolia Officinalis Dietary Supplement on Immune Biomarkers in Subjects With Psoria · NA · recruiting
- NCT07449234 — A Study of Guselkumab After Switching From Ustekinumab in Participants With Moderate to Severe Psoriasis · recruiting
- NCT07234838 — Effect of Anti-Psoriatic Biologics on Risk of Anogenital Warts (CONDYPSO) · recruiting
- NCT07194200 — Safety and Efficacy of Lactobacillus Plantarum for Psoriasis: A Randomized Double-Blind Placebo-Controlled Trial · Phase 2 · recruiting
- NCT07250997 — PALLAS Laser for Skin Diseases · NA · recruiting
Other University Hospital Schleswig-Holstein trials
Trials by the same sponsor.
- NCT07591376 — A Reminder App to Improve Physical Activity During Radiotherapy for Lung Cancer - a Pre-study in Healthy Volunteers · NA · completed
- NCT07286747 — Efficacy and Safety of Oral Controlled-release Nicotinic Acid (CIR-NA) for the Remission of Prediabetes. (CONCEPT) · Phase 2 · recruiting
- NCT07380815 — Physical Activity During Radiation Therapy for Lung Cancer · not yet recruiting
- NCT07148336 — Identification of Chemotherapy-induced Peripheral Neuropathy · NA · not yet recruiting
- NCT07444801 — Intervention With Tralokinumab in Patients With Moderate-to-severe Atopic Dermatitis With Genital Impact · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07244744 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospital Schleswig-Holstein
- Last refreshed: 24 November 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07244744.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing